November 29, 2016 - By Nellie Frank · 0 Comments
The stock of Caredx Incorporated (NASDAQ:CDNA) registered an increase of 0.17% in short interest. CDNA’s total short interest was 59,900 shares in November as published by FINRA. Its up 0.17% from 59,800 shares, reported previously. With 9,500 shares average volume, it will take short sellers 6 days to cover their CDNA’s short positions. The short interest to Caredx Incorporated’s float is 0.41%. The stock decreased 2.60% or $0.1 on November 28, hitting $3.75. CareDx Inc (NASDAQ:CDNA) has declined 17.76% since April 26, 2016 and is downtrending. It has underperformed by 23.02% the S&P500.
CareDx, Inc. is a molecular diagnostics company. The company has a market cap of $84.16 million. The Firm is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. It currently has negative earnings. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test , is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Insitutional Activity: The institutional sentiment increased to 1.71 in Q2 2016. Its up 0.14, from 1.57 in 2016Q1. The ratio is positive, as 1 funds sold all CareDx Inc shares owned while 6 reduced positions. 4 funds bought stakes while 7 increased positions. They now own 5.81 million shares or 18.74% more from 4.90 million shares in 2016Q1.
Walleye Trading Ltd Liability holds 560 shares or 0% of its portfolio. Natl Bank Of America De reported 201 shares or 0% of all its holdings. California Pub Employees Retirement Sys accumulated 175,000 shares or 0% of the stock. Gagnon Llc holds 3.54% of its portfolio in CareDx Inc (NASDAQ:CDNA) for 952,464 shares. Goldman Sachs Group Inc Inc holds 54,141 shares or 0% of its portfolio. Blackrock Institutional Trust Na last reported 5,838 shares in the company. Paragon Assocs Paragon Assocs Ii Joint Venture accumulated 1.17 million shares or 4.95% of the stock. Spark Inv Mgmt Limited Liability Company holds 16,400 shares or 0.01% of its portfolio. Barclays Public Limited Company holds 68 shares or 0% of its portfolio. Blackrock Invest Mngmt Ltd Liability has 0% invested in the company for 1,496 shares. Thompson Davis & holds 0.01% of its portfolio in CareDx Inc (NASDAQ:CDNA) for 2,000 shares. Morgan Stanley owns 5,859 shares or 0% of their US portfolio. Gagnon Secs Lc has 2.76% invested in the company for 1.34 million shares. Acuta Cap Ptnrs Limited owns 64,627 shares or 0.13% of their US portfolio. Moreover, Highland Cap Mgmt Lp has 0.03% invested in CareDx Inc (NASDAQ:CDNA) for 167,581 shares.
Insider Transactions: Since September 21, 2016, the stock had 3 insider purchases, and 0 selling transactions for $794,511 net activity. 10,000 shares were bought by Whitson Todd, worth $40,000 on Monday, September 26. Nelles Mitchell J also bought $40,000 worth of CareDx Inc (NASDAQ:CDNA) shares. GAGNON NEIL had bought 178,686 shares worth $714,511.
Out of 3 analysts covering CareDx (NASDAQ:CDNA), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. CareDx has been the topic of 4 analyst reports since September 25, 2015 according to StockzIntelligence Inc. The stock of CareDx Inc (NASDAQ:CDNA) has “Buy” rating given on Tuesday, June 14 by Mizuho. On Friday, September 25 the stock rating was initiated by Craig Hallum with “Buy”. Raymond James downgraded the shares of CDNA in a report on Monday, September 28 to “Market Perform” rating.
CareDx, Inc., incorporated on December 21, 1998, is a molecular diagnostics company. The Firm is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap) is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. AlloMap is a non-invasive method recommended in the International Society for Heart and Lung Transplantation (ISHLT) patient care guidelines for surveillance of heart transplant rejection in patients 15 years of age or older.
Another recent and important CareDx Inc (NASDAQ:CDNA) news was published by Prnewswire.com which published an article titled: “CMS Proposal Threatens Availability Of Standard Of Care Blood Test To Heart …” on October 03, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank